PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework

Kevin Haninger, Vice President for International Advocacy, PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) is sounding an alarm over the Japanese government’s proposed cost-effectiveness assessment (CEA) scheme, arguing that it is overly reliant on the ICER (incremental cost-effectiveness...read more